For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...
Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...
Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships wit ...
Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and ...
An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...
As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term ...
The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the ...
Popular anti-diabetes and obesity drug Mounjaro, containing the active ingredient tirzepatide, is now available in India in a ...
US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback